Mays Cancer Center

Medicine & Life Sciences

1. Prostatic Neoplasms 100%
2. Neoplasms 54%
3. Multiple Myeloma 34%
4. Cell Transplantation 34%
5. Prostate 29%
6. Survival 28%
7. Breast Neoplasms 28%
8. Finasteride 26%
9. Therapeutics 26%
10. Transplants 24%
11. Autologous Transplantation 24%
12. Chemoprevention 23%
13. Prostate-Specific Antigen 23%
14. Primary Myelofibrosis 20%
15. Drug Therapy 20%
16. Progression-Free Survival 19%
17. Hematopoietic Stem Cell Transplantation 19%
18. Recurrence 17%
19. Carcinoma 16%
20. Bone Marrow 16%
21. Prostatectomy 16%
22. Confidence Intervals 15%
23. Stem Cell Transplantation 14%
24. Biopsy 13%
25. Allogeneic Cells 13%
26. Autografts 12%
27. reolysin 12%
28. Lymphoma 12%
29. Non-Hodgkin's Lymphoma 12%
30. Mortality 11%
31. Homologous Transplantation 11%
32. Placebos 11%
33. Apoptosis 11%
34. Transplantation 11%
35. Stem Cells 11%
36. Heterografts 11%
37. Fedratinib 11%
38. Digital Rectal Examination 10%
39. Bortezomib 10%
40. INCB018424 10%
41. Triple Negative Breast Neoplasms 10%
42. Head and Neck Neoplasms 10%
43. Autophagy 9%
44. Renal Cell Carcinoma 9%
45. Clinical Trials 9%
46. Biomarkers 9%
47. Safety 9%
48. Hormones 8%
49. Early Detection of Cancer 8%
50. Population 8%
51. Polycythemia Vera 8%
52. Selenium 8%
53. Paclitaxel 8%
54. irofulven 8%
55. Neoplasm Metastasis 8%
56. Quality of Life 7%
57. Peripheral Blood Stem Cells 7%
58. Bone Marrow Transplantation 7%
59. Radiotherapy 7%
60. Adenocarcinoma 7%
61. Pancreatic Neoplasms 7%
62. ErbB Receptors 7%
63. Watchful Waiting 7%
64. Incidence 7%
65. pevonedistat 7%
66. Vitamin E 7%
67. Randomized Controlled Trials 7%
68. Cetuximab 7%
69. Pediatrics 7%
70. Follicular Lymphoma 6%
71. gemcitabine 6%
72. Vorinostat 6%
73. Catheters 6%
74. Growth 6%
75. Histone Deacetylase Inhibitors 6%
76. Hematologic Neoplasms 6%
77. Estrogen Receptors 6%
78. Hispanic Americans 6%
79. Janus Kinase Inhibitors 6%
80. Lymphoma, Large B-Cell, Diffuse 6%
81. Transurethral Resection of Prostate 6%
82. Androgens 5%
83. Docetaxel 5%
84. Urinary Bladder 5%
85. Hodgkin Disease 5%
86. Blood Cells 5%
87. Disease Progression 5%
88. Costs and Cost Analysis 5%
89. Acute Myeloid Leukemia 5%
90. Registries 5%
91. Carboplatin 5%
92. Testosterone 5%
93. Neoadjuvant Therapy 5%
94. Immunotherapy 5%
95. Urinary Bladder Neoplasms 5%
96. Irinotecan 5%
97. 1-(2-(2-((7-chloroquinolin-4-yl)amino)ethyl-methylamino)ethylamino)-4-methylthioxanthen-9-one 5%
98. Pharmacokinetics 5%
99. eribulin 5%
100. Unrelated Donors 5%